Intravitreal infliximab in experimental endotoxin-induced uveitis

European Journal of Ophthalmology

Volumn 19, Issue 5, 2009, Pages 818-823

  Hosseini, Hamid ^a   Safaei, Akbar ^b   Khalili, Mohammad R ^a   Nowroozizadeh, Behdokht ^b   Eghtedari, Masoometh ^a   Farvardin, Mohsen ^a   Nowroozizadeh, Sarah ^a   Tolide Ie, Hamid R ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Immunosuppresion; Infliximab; Ocular drug therapy; Uveitis

Indexed keywords

ENDOTOXIN; GENTAMICIN; INFLIXIMAB; TIMOLOL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL RABBIT; EYE INFLAMMATION; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; UVEITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; DISEASE MODELS, ANIMAL; EYE PROTEINS; INJECTIONS; LIPOPOLYSACCHARIDES; RABBITS; SALMONELLA TYPHIMURIUM; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; VITREOUS BODY;

EID: 70549095941     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210901900521     Document Type: Article

References (25)

1. De Vos AF, Hoekzema R, Kijlstra A. Cytokines and uveitis: a review. Curr Eye Res 1992; 11: 581-97.
2. de Vos AF, van Haren MA, Verhagen C, Hoekzema R, Kijlstra A. Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994; 35: 1100-6.
3. Franks WA, Limb GA, Stanford MR, et al. Cytokines in human intraocular inflammation. Curr Eye Res 1992; Suppl: 187-91.
4. Demir T, Godekmerdan A, Balbaba M, Turkcuoglu P, Ilhan F, Demir N. The effect of infliximab, cyclosporine A and recombinant IL-10 on vitreous cytokine levels in experimental autoimmune uveitis. Indian J Ophthalmol 2006; 54: 241-5.
5. Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Exp Ophthalmol 2006; 34: 365-74.
6. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007; 27: 399-413.
7. Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007; 125: 895-900.
8. Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol 2007; 144: 844-9.
9. Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 2006; 33: 231-7.
10. Richards JC, Tay-Kearney ML, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol 2005; 33: 461-8.
11. Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol 2005; 26: 83-92.
12. Ersanli D, Karadayi K, Toyran S, et al. The efficacy of hyperbaric oxygen for the treatment of experimental uveitis induced in rabbits. Ocul Immunol Inflamm 2005; 13: 383-8.
13. Verma MJ, Mukaida N, Vollmer-Conna U, Matsushima K, Lloyd A, Wakefield D. Endotoxin-induced uveitis is partially inhibited by anti-IL-8 antibody treatment. Invest Ophthalmol Vis Sci 1999; 40: 2465-70.
14. Panzer S, Madden M, Matsuki K. Interaction of IL-1 beta IL-6 and tumour necrosis factor-alpha (TNF-alpha) in human T cells activated by murine antigens. Clin Exp Immunol 1993; 93: 471-8.
15. Fleisher LN, Ferrell JB, McGahan MC. Ocular inflammatory effects of intravitreally injected tumor necrosis factor-alpha and endotoxin. Inflammation 1990; 14: 325-35.
16. Portillo G, Turner M, Chantry D, Feldmann M. Effect of cytokines on HLA-DR and IL-1 production by a monocytic tumour, THP-1. Immunology 1989; 66: 170-5.
17. Brito BE, O'Rourke LM, Pan Y, Anglin J, Planck SR, Rosenbaum JT. IL-1 and TNF receptor-deficient mice show decreased inflammation in an immune complex model of uveitis. Invest Ophthalmol Vis Sci 1999; 40: 2583-9.
18. Vilcek J, Lee TH. Tumor necrosis factor: new insights into the molecular mechanisms of its multiple actions. J Biol Chem 1991; 266: 7313-6.
19. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992; 13: 151-3.
20. de Boer JH, Hack CE, Verhoeven AJ, et al. Chemoattractant and neutrophil degranulation activities related to interleukin-8 in vitreous fluid in uveitis and vitreoretinal disorders. Invest Ophthalmol Vis Sci 1993; 34: 3376-85.
21. Kawashima H. Chemokines: their role in immunotherapy for intraocular inflammation. Ocul Immunol Inflamm 2003; 11: 83-90.
22. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005; 123: 903-12.
23. Hsu J. Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol 2007; 18: 235-9.
24. Giansanti F, Ramazzotti M, Vannozzi L, et al. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci 2008; 49: 1151-6.
25. Olson JL, Courtney RJ, Mandava N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol 2007; 125: 1221-4.